4.5 Article

The channel-kinase TRPM7 regulates antigen gathering and internalization in B cells

Journal

SCIENCE SIGNALING
Volume 11, Issue 533, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.aah6692

Keywords

-

Funding

  1. Canadian Institutes of Health Research [MOP-136808]
  2. Natural Sciences and Engineering Research Council of Canada (NSERC) [RGPIN 418756-12]
  3. Canada Research Chair [905-231134]
  4. NSERC graduate student fellowships
  5. NSERC Undergraduate Student Research Award
  6. NIH [5R21AI088421, 5R21AI107503, 5R01GM090123]

Ask authors/readers for more resources

Members of the transient receptor potential (TRP) family of ion channels are cellular sensors involved in numerous physiological and pathological processes. We identified the TRP subfamily M member 7 (TRPM7) channel-kinase as a previously uncharacterized regulator of B cell activation. We showed that TRPM7 played a critical role in the early events of B cell activation through both its ion channel and kinase functions. DT40 B cells deficient in TRPM7 or expressing a kinase-deficient mutant of TRPM7 showed defective gathering of antigen and prolonged B cell receptor (BCR)signaling. We showed that lipid metabolism was altered in TRPM7-deficient cells and in cells expressing a kinase-deficient mutant of TRPM7 and suggest that PLC-gamma 2 may be a target of the kinase activity of TRPM7. Primary B cells that expressed less TRPM7 or were treated with a pharmacological inhibitor of TRPM7 also displayed defective antigen gathering and increased BCR signaling. Finally, we demonstrated that blocking TRPM7 function compromised antigen internalization and presentation to T cells. These data suggest that TRPM7 controls an essential process required for B cell affinity maturation and the production of high-affinity antibodies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

The ion channel TRPM7 is required for B cell lymphopoiesis

Mithunah Krishnamoorthy, Fathima Hifza Mohamed Buhari, Tiantian Zhao, Patrick M. Brauer, Kyle Burrows, Eric Yixiao Cao, Vincent Moxley-Paquette, Arthur Mortha, Juan Carlos Zuniga-Pflucker, Bebhinn Treanor

SCIENCE SIGNALING (2018)

Article Biochemistry & Molecular Biology

The channel-kinase TRPM7 regulates antigen gathering and internalization in B cells

Mithunah Krishnamoorthy, Laabiah Wasim, Fathima Hifza Mohamed Buhari, Tiantian Zhao, Trisha Mahtani, Josephine Ho, Sohee Kang, Francina Deason-Towne, Anne-Laure Perraud, Carsten Schmitz, Bebhinn Treanor

SCIENCE SIGNALING (2018)

Article Biochemistry & Molecular Biology

The ion channel TRPM7 is required for B cell lymphopoiesis

Mithunah Krishnamoorthy, Fathima Hifza Mohamed Buhari, Tiantian Zhao, Patrick M. Brauer, Kyle Burrows, Eric Yixiao Cao, Vincent Moxley-Paquette, Arthur Mortha, Juan Carlos Zuniga-Pflucker, Bebhinn Treanor

SCIENCE SIGNALING (2018)

Review Cell Biology

Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy

Mithunah Krishnamoorthy, Lara Gerhardt, Saman Maleki Vareki

Summary: Myeloid cells can transform into myeloid-derived suppressor cells during cancer progression or chronic inflammation, inhibiting anti-tumor immunity. Overcoming the suppression caused by MDSCs is a major obstacle in cancer immunotherapy, highlighting the importance of understanding the mechanisms behind how MDSCs promote tumor growth for improving and developing new therapies.

CELLS (2021)

Review Oncology

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges

Mithunah Krishnamoorthy, John G. Lenehan, Saman Maleki Vareki

Summary: Neoadjuvant immunotherapy shows promise in high-risk resectable diseases by increasing pathological response rate and prolonging relapse-free survival, with potential significance in preventing relapses. However, randomized controlled trials are needed to confirm its efficacy across different tumor types.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Review Oncology

Immunomodulation in Pancreatic Cancer

Mithunah Krishnamoorthy, John G. Lenehan, Jeremy P. Burton, Saman Maleki Vareki

CANCERS (2020)

No Data Available